| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | AXSM | Stock Option (Right to Buy) | 14 Oct 2024 | Common Stock | 38,710 | $70.73 | Direct | F1 | ||||||
| holding | AXSM | Stock Option (Right to Buy) | 14 Oct 2024 | Common Stock | 23,593 | $84.00 | Direct | F2 | ||||||
| holding | AXSM | Restricted Stock Units | 14 Oct 2024 | Common Stock | 16,302 | Direct | F3, F4 | |||||||
| holding | AXSM | Restricted Stock Units | 14 Oct 2024 | Common Stock | 12,956 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | The option was granted on September 25, 2023. 25% of the option vests on the one (1) year anniversary of the date of grant, with the remaining 75% to vest in equal increments on a quarterly basis over a four (4) year period, until fully vested. |
| F2 | The option was granted on February 27, 2024 and vests in equal increments on a quarterly basis over a four (4) year period, until fully vested. |
| F3 | The restricted stock units ("RSU") was granted on September 25, 2023. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on September 25, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability) of the reporting person, or (iii) seven (7) years from the date of grant. |
| F4 | Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| F5 | The RSUs were granted on February 27, 2024. 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Plan), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability) of the reporting person, or (iii) seven (7) years from the date of grant. |
1) Exhibit List Exhibit 24 - Power of Attorney; 2) Ari Maizel was promoted to Chief Commercial Officer from his previous position as Executive Vice President, Head of Commercial. Mr. Maizel joined Axsome Therapeutics, Inc. (the "Issuer") in September 2023.